No Data
No Data
Ono Pharmaceutical: Half-Year Report - Term 77 (2024/04/01 - 2025/03/31)
Ono Pharmaceutical: Confirmation letter
Equillium Shares Are Trading Lower After the Company Announced Ono Pharmaceutical Has Made the Business Decision to Allow the Expiration of Its Option to Acquire Equillium's Rights to Itolizumab
Ono Pharmaceutical Makes Strategic Business Decision to Allow Itolizumab Option to Expire
Ono Pharmaceutical: Revision of earnings forecasts and introduction of core-based performance
Ono Pharmaceutical: Interim Accounting Period Fiscal Period Ending March 2025 (April to September) Supplementary Financial Information (Consolidated IFRS)
No Data
No Data